20/20 BIOLABS, INC. Research and Development Expense
20/20 BIOLABS, INC. (AIDX) reported Research and Development Expense of $257.63 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-14
- 20/20 BIOLABS, INC. research and development expense for the quarter ending 2026-06-30 was $257.63K, a 32.72% increase year-over-year.
- 20/20 BIOLABS, INC. research and development expense for the quarter ending 2026-03-31 was $153.48K, a 12.17% increase year-over-year.
- 20/20 BIOLABS, INC. research and development expense for the quarter ending 2025-06-30 was $194.12K.
- 20/20 BIOLABS, INC. research and development expense for the quarter ending 2025-03-31 was $136.83K.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 12 month |
|---|---|---|---|
| 2026-06-30 | $257.63K 10-Q · filed 2026-08-14 | $411.11K 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $153.48K 10-Q · filed 2026-05-20 | ||
| 2025-12-31 | $592.57K POS AM · filed 2026-04-06 | ||
| 2025-06-30 | $194.12K 10-Q · filed 2026-08-14 | $330.95K 10-Q · filed 2026-08-14 | |
| 2025-03-31 | $136.83K 10-Q · filed 2026-05-20 | ||
| 2024-12-31 | $1.26M POS AM · filed 2026-04-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGENOMICS INC (NEO) | United States | $2.514B | -35.96 |